The challenges of adherence and persistence with iron chelation therapy-Reference-Cited by-同舟云学术

The challenges of adherence and persistence with iron chelation therapy

Published:2011-10-13 Issue:5 Volume:94 Page:453-460
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Porter John B.,Evangeli Michael,El-Beshlawy Amal

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-011-0927-3.pdf

Reference40 articles.

1. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–7.

2. World Health Organization. Adherence to long-term therapies. Evidence for action. 2003. http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf .

3. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18:277–87.

4. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102:17–24.

5. Ferriprox prescribing information. 2007. http://www.ferriprox.com .

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Iron overload: The achilles heel of β-thalassemia;Transfusion Clinique et Biologique;2024-08

2. Management of transfusion-dependent β-thalassemia (TDT): Expert insights and practical overview from the Middle East;Blood Reviews;2024-01

3. Combination chelation therapy;Annals of the New York Academy of Sciences;2023-08-18

5. Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years;Blood Advances;2023-02-21